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Sylvatic dengue viruses (DENV) are both evolutionarily and ecologically distinct from human DENV and
are maintained in an enzootic transmission cycle. Evidence of sylvatic human infections from West
Africa and Southeast Asia suggests that sylvatic DENV come into regular contact with humans. Thus,
this potential of emergence into the human transmission cycle could limit the potential for eradicating
this cycle with vaccines currently in late stages of development. We assessed the likelihood of sylvatic
DENV-4 emergence in the face of natural immunity to current human strains and vaccination with two
DENV-4 vaccine candidates. Our data indicate homotypic neutralization of sylvatic and human DENV-4
strains by human primary convalescent and vaccinee sera but limited heterotypic immunity. These
results suggest that emergence of sylvatic strains into the human cycle would be limited by homotypic
immunity mediated by virus neutralizing antibodies produced by natural infection or vaccination.
& 2013 Elsevier Inc. All rights reserved.Introduction
Dengue viruses (DENV) are arthropod-borne viruses (arbo-
viruses) in the genus Flavivirus (family Flaviviridae) that utilize
Aedes (Stegomyia) spp., primarily Ae. aegypti and to a lesser degree
Ae. albopictus, as vectors for transmission in urban and peri-urban
settings (urban transmission cycle). In Southeast Asia and West
Africa, DENV are also transmitted in an enzootic cycle between
non-human primates and arboreal Aedes spp. mosquitoes. There
are four antigenically distinct but genetically related serotypes
(DENV-1,-2, -3 and -4) within the dengue (DEN) antigenicll rights reserved.
dical Branch, Department of
ty, Center for Biodefense and
, 301 University Boulevard,
9 266 6810.
tmail.com (N. Vasilakis).complex (Calisher et al., 1989). Unlike most arboviruses, DENV
are extremely restricted in their natural vertebrate host range,
which most likely includes only primates. Currently, all four
DENV serotypes can be found in nearly all urban and peri-urban
tropical and subtropical environments where Ae. aegypti is pre-
sent. By current estimates this distribution puts over half of the
global human population at risk for infection. The impact of
DENV infections on human health is enormous; over 200 million
infections and 2 million cases of dengue hemorrhagic fever
(DHF) occur each year, with a case fatality rate of up to 5%
(Kyle and Harris, 2008). Most profoundly, the majority of the
DEN-associated disease in hyperendemic regions is borne by
children (Clark et al., 2005; Mathers et al., 2007; Witayathaworn-
wong, 2005), although recent evidence from Southeast Asia and
Latin America suggests that adults are also at high risk (Fox et al.,
2011; Guilarde et al., 2008; Hanafusa et al., 2008; Koh et al., 2008;
Siqueira et al., 2005; Wichmann et al., 2004), particularly in urban
Table 1
Sylvatic and human DENV strains used in this study.
Isolatea Serotype Hostb Passage historyc Epidemiological typed Location Year GenBank accession noe
P72-1244 1 Ae. niveus ?, C6/36-3 Sylvatic?e Malaysia 1975 EF457905
OBS7690 1 Human C6/36-3 Human Bolivia 1999 N/Af
16681 2 Human BSC-1 –X, MK2–6, Rh. Macaque – 1,Tx.
Amboinensis – 2, C6/36–4, MK2–1, C6/36–1
Human Thailand 1964 U87411
DKD811 2 Human C6/36-4 Sylvatic Malaysia 2008 FJ467493
P8-1407 2 Sentinel monkey SM – 3, C6/36–2 Sylvatic Malaysia 1970 EF105379
JKT85-934 3 Human ?, NHP-1, C6/36-2 Human Indonesia 1985 N/Af
814669g 4 Human MK2-1, C6/36-4 Human Dominica 1981 AF326573
H241 4 Human SM-17, C6/36-4 Human The Philippines 1956 AY947539
India G11337 4 Human ?, C6/36-2 Human India 1961 JF262783
INH6412 4 Human C6/36-2 Human Venezuela 1995 JF262781
Haiti73 4 Human C6/36-3 Human Haiti 1994 JF262782
P75-215 4 Sentinel monkey Ae. niveus, C6/36-3 Sylvatic Malaysia 1975 EF457906
P75-514 4 Sentinel monkey Presbytis cristata-2, C6/36-2 Sylvatic Malaysia 1975 JF262780
P73-1120 4 Sentinel monkey Presbytis cristata-1, C6/36-2 Sylvatic Malaysia 1973 JF262779
a DENV isolates were obtained from the UTMB World Reference Center for Emerging Viruses and Arboviruses (WRCEVA).
b Source of virus isolation.
c SM—suckling mouse; C6/36—Ae. albopictus cell line; MK2—Rhesus monkey kidney cells; BSC-1—African green monkey kidney cells; AP61—Aedes pseudoscutellaris
cell line;?—unknown number of passages prior been deposited to WRCEVA.
d Endemic indicates human or Ae. aegypti isolates or those associated with peridomestic transmission; sylvatic indicates sentinel monkey or canopy-dwelling mosquito
isolate.
e Although DENV-1 P72-1244 strain had been identiﬁed initially by Rudnick (Rudnick, 1986) as sylvatic, subsequent analyses suggest that this strain may represent a
spill-back from the human transmission cycle (Vasilakis et al., 2011).
f N/A – not available.
g Kindly provided by Dr Anna Durbin.
A.P. Durbin et al. / Virology 439 (2013) 34–41 35areas that are transitioning or have already transitioned to
hyperendemicity.
Phylogenetic (Chen and Vasilakis, 2011; Rico-Hesse, 1990;
Twiddy et al., 2003; Vasilakis et al., 2008b; Wang et al., 2000)
and ecological studies (Cordellier et al., 1983; Hervy et al., 1984;
Monlun et al., 1992; Roche et al., 1983; Rudnick, 1965, 1978,
1984, 1986; Smith, 1956, 1958) indicate that the ancestral
sylvatic DENV are both ecologically and evolutionarily indepen-
dent from the current endemic DENV circulating within urban
transmission cycles. However, data from West Africa and South-
east Asia suggest that sylvatic DENV come into regular contact
with humans. For example, in West Africa the gallery forest-
dwelling mosquito, Ae. furcifer, which is highly susceptible to
sylvatic DENV infection (Diallo et al., 2005), disperses into villages
and may be responsible for sylvatic DENV infection of humans
(Diallo et al., 2003; Fagbami et al., 1977). In Southeast Asia, Ae.
albopictus may transfer sylvatic DENV from the forest into human
habitats (Rudnick, 1986). Sylvatic DENV infection can cause
human disease in both rural peridomestic and urban settings as
documented by spillover epidemics (Carey et al., 1971; Vasilakis
et al., 2008c), and human infections in West Africa (Franco et al.,
2011; Monlun et al., 1992; Robin et al., 1980; Saluzzo et al., 1986)
and Southeast Asia (Cardosa et al., 2009). Clinical illness due to
sylvatic DENV not only is indistinguishable from classic dengue
fever (DF), but also has the potential to progress to severe disease
(Cardosa et al., 2009; Franco et al., 2011). Because the only means
to determine whether the DENV strain causing human infection is
from the sylvatic or the urban transmission cycle is by sequencing
the virus genome, human infection by sylvatic strains is often
misclassiﬁed etiologically as due to urban strains.
Collectively, these observations combined with: (i) experimental
evidence in models of human (Vasilakis et al., 2007) and mosquito
infection (Diallo et al., 2005, 2008) (Hanley and Vasilakis, unpublished
data) that adaptation is not required for urban transmission; and (ii)
the continuing risk of DENV emergence from the sylvatic cycle
resulting in human infection, which can manifest as symptomatic
dengue disease, suggest that sylvatic dengue spillover may occur at a
greater frequency than is currently recognized. A recent studyshowed broad neutralization by vaccinated monkey serum against a
large panel of DENV-1-4, including a DENV-2 sylvatic strain (Barban
et al., 2012). Our earlier study (Vasilakis et al., 2008a), evaluating the
neutralization capacity of convalescent sera collected from dengue
vaccine recipients and from DENV-2 and DENV-3 patients following
primary infection, also suggested that the emergence of sylvatic
DENV strains into the human transmission cycle would be limited
by homotypic humoral immunity.
In this study, to assess the likelihood of current sylvatic DENV-
4 re-emergence (emergence of extant sylvatic DENVs into the
human transmission cycle) in the face of immunity induced by
current urban-circulating DENV strains or vaccine candidates, we
tested sera collected from DENV-4 vaccine recipients and
convalescent-phase sera from DENV-infected patients against
geographically and genetically diverse sylvatic and human
DENV-4 strains (Table 1).Results and discussion
Neutralization studies of human vaccinee sera
For vaccination to achieve effective immunity against DEN
disease, the immune response must be effective against all four
DENV serotypes and must be long-lived. Natural infection with
DENV results in lifelong protection against reinfection with the
same serotype (Halstead, 1974; Okuno et al., 1983;
Papaevangelou and Halstead, 1977; Rosen, 1986; Sabin, 1952;
Tadano et al., 1983) but only in transient cross-protection against
heterotypic serotypes (Guirakhoo et al., 2006; Sabin, 1952).
Homotypic immunity is mediated by neutralizing antibodies
directed mainly against the viral envelope (E) protein (Crill and
Roehrig, 2001; Kaufman et al., 1987; Roehrig et al., 1998) and
other minor antigens located in the viral membrane [(M)
(Kaufman et al., 1989) and non-structural 1 (NS1) (Schlesinger
et al., 1986) proteins] as well as by cell-mediated immunity.
However, heterotypic immunity is associated with cross-reactive
A.P. Durbin et al. / Virology 439 (2013) 34–4136neutralizing antibodies to E and prM that decline rapidly after
infection (Pengsaa et al., 2006; Sabin, 1952).
Previously, we assessed the likelihood of current sylvatic DENV
re-emergence in the face of immunity to current vaccine candidates,
including the DENV-4 candidate vaccine rDEN4D30, by evaluating
the neutralizing capacity of sera from DENV4D30 vaccinees against
reference sylvatic and human DENV-4 strains (Vasilakis et al.,
2008a). Here, we assessed the potential of all available sylvatic
DENV-4 strains to re-emerge in the face of immunity to an
expanded set of human strains, as well as the more attenuated
DENV-4 rDEN4D30-200,201 and rDEN4D30 vaccine candidates, by
evaluating the neutralizing capacity of sera from human DENV
vaccinees and convalescent patients from Puerto Rico, Mexico,
Singapore, Sri Lanka, the West Indies, Honduras, and Thailand.
Sera collected at 42 days post-vaccination from 7 and 10
placebo-controls participating in the clinical trials evaluating
rDEN4D30-200,201 and rDEN4D30, respectively, were unable to
neutralize any DENV tested (PRNT60o20). Sera collected from all
rDEN4D30-200,201 vaccinees were previously shown to neutralize
the parent DENV-4 strain 814669 (McArthur et al., 2008) and were
not retested in the current study. Overall, sera from 16/19
rDEN4D30-200,201vaccinees neutralized some or all of the DENV-
4 strains. Weak to modest (PRNT60¼20–160) homotypic neutraliza-
tion was exhibited by vaccinee sera (Table 2). Sera from 13/19
vaccinees neutralized all of the DENV-4 tested, while sera from three
additional vaccinees neutralized all viruses tested except for the
India G11337 (3 test sera 214.01.14, 214.01.16, 214.01.18 ) and the
H241 strains (test serum 214.01.14). Weak to modest (PRNT60¼20–
160) homotypic neutralization responses were exhibited by sera
collected at 42 days post vaccination (Table 2). The levels of
homotypic neutralization further decreased 180 days post vaccina-
tion (PRNT60¼20–40) (data not shown). Similarly, sera collected
from 21/22 persons vaccinated with rDEN4D30 neutralized some
(14) or all (7) of the DENV-4 tested, and several sera from other
persons were unable to neutralize human or sylvatic DENV-4 strains
(Table 3). The homotypic neutralization responses exhibited by sera
collected 42 days after vaccination ranged from weak to strongTable 2
Homotypic and Heterotypic Neutralizationa by DENV-4 Sera from Persons Inoculated w
DENV-4
Immune sera
Virus
Endemic DENV-4 Sylvatic DENV–4
814669 H241 India G11337 INH6412 Haiti73 P75-215 P75-51
214.01.01 NT 40 40 80 40 40 20
214.01.06 NT 20 20 40 40 20 40
214.01.08 NT 80 40 40 20 40 40
214.01.09 NT o20 o20 o20 o20 o20 o20
214.01.11 NT 40 40 40 80 80 40
214.01.12 NT 20 20 80 40 20 40
214.01.13 NT 40 20 80 40 20 20
214.01.14 NT o20 o20 40 20 20 20
214.01.16 NT 40 o20 40 20 20 20
214.01.18 NT 20 o20 20 20 20 20
214.01.19 NT 160 40 160 80 80 80
214.01.20 NT 20 20 20 40 20 40
214.01.21 NT 80 80 80 40 80 80
214.01.22 NT NT 80 80 40 40 20
214.01.23 NT 80 80 80 40 40 40
214.01.25 NT o20 o20 o20 o20 o20 o20
214.01.26 NT 80 20 80 40 80 40
214.01.27 NT o20 o20 o20 o20 o20 o20
214.02.12 NT 40 20 80 160 80 40
NT – not tested.
a 60% reduction measured by Plaque Reduction Neutralization Test (PRNT60).
b Sylvatic DENV-2 strains.
c Sylvatic DENV-1 strain.(PRNT60¼20 to 4640) (Table 3) (sera collected 180 days post
vaccination were not tested) and were collectively more potently
neutralizing than sera from the rDEN4D30-200,201 vaccinees (mean
log titers 1:40 and 1:28, respectively, P¼0.0163), consistent with
greater attenuation of the rDEN4D30-200,201 virus. Sera from all
but two persons vaccinated with either rDEN4D30-200,201 or
rDEN4D30 failed to neutralize heterotypic human DENV-1–3 or
sylvatic DENV-2 (PRNT60o20) (Tables 2 and 3). Serum from patient
JHU02 exhibited a strong heterotypic response to the sylvatic DENV-
2 DKD811 strain (Cardosa et al., 2009). Interestingly serum from one
vaccinated subject (JHU 22) exhibited a modest to relatively strong
heterotypic neutralizing response to DENV-1 and -3 (PRNT60¼40–
4640) and a robust neutralization titer (41280) to DENV-2,
suggesting a secondary antibody response (previous DENV-2 infec-
tion), or possibly an inapparent West Nile virus infection and
‘original antigenic sin’ (Halstead et al., 1983; Kuno et al., 1993).
However, there were stringent eligibility criteria for this trial,
including absence of prior exposure to ﬂaviviruses (Durbin et al.,
2006), and this volunteer was previously found to be seronegative
by PRNT to DENV-1-4, yellow fever (YFV) and WNV and by
hemagglutination-inhibition assay to Saint Louis encephalitis virus
(SLEV), WNV, and Japanese encephalitis virus (JEV) prior to vaccina-
tion. Furthermore, it is very unlikely that this volunteer (JHU 22)
would have been exposed to any ﬂavivirus other than WNV because
he/she was a Baltimore resident with no travel history to any DENV-
endemic countries. We reported a similar observation previously
(Vasilakis et al., 2008a). The broad heterotypic response after
vaccination or previous, unknown exposure could be due to anti-
genic mismatch between the vaccine and DENV strains used for the
PRNT (Lanata et al., 2012; Sabchareon et al., 2012).
The vaccinee sera offer a unique opportunity to explore the
relationship between neutralization and DENV genetic diversity.
Because the sequences are known for the vaccine strain and for
the endemic and sylvatic strains used in the assays, it is possible
to test the relationship between differences in neutralization
titers of sera and genetic differences among the viruses used in
the assays. Using published sequences for the rDEN4D30 vaccineith Candidate rDEN4D30-200,201 DENV-4 Vaccine at day 42 post vaccination.
DENV-2 DENV-3 DENV-1
4 P73-1120 16681 DKD811b P8-1407b JKT85-934 OBS7690 P72-1244c
20 o20 o20 o20 o20 o20 o20
20 o20 o20 o20 o20 o20 o20
40 o20 o20 o20 o20 o20 o20
o20 o20 o20 o20 o20 o20 o20
20 o20 o20 o20 o20 o20 o20
20 o20 o20 o20 o20 o20 o20
20 o20 o20 o20 o20 o20 o20
20 o20 o20 o20 o20 o20 o20
20 NT NT o20 o20 o20 o20
20 o20 o20 o20 o20 o20 o20
40 o20 NT o20 o20 o20 o20
20 o20 o20 o20 o20 o20 o20
40 o20 o20 o20 o20 o20 o20
20 NT NT NT o20 NT NT
20 o20 o20 o20 o20 o20 o20
o20 o20 o20 o20 o20 o20 o20
20 o20 o20 o20 o20 o20 o20
o20 o20 o20 o20 o20 o20 o20
20 o20 o20 o20 o20 o20 o20
Table 3
Homotypic and Heterotypic Neutralizationa by DENV-4 Sera from Persons Inoculated with Candidate rDEN4D30 DENV-4 Vaccine at day 42 post vaccination.
DENV-4
Immune sera
Virus
Endemic DENV-4 Sylvatic DENV-4 DENV-2 DENV-3 DENV-1
814669 H241 India G11337 INH6412 Haiti73 P75-215 P75-514 P73-1120 16681 DKD811b P8-1407b JKT85-934 OBS7690 P72-1244c
JHU 01 4640 160 4640 4640 320 o20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 02 20 40 80 80 20 20 80 160 o20 4640 o20 o20 o20 o20
JHU 03 320 o20 o20 320 20 20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 04 160 o20 20 4640 o20 40 20 o20 o20 o20 o20 o20 o20 o20
JHU 05 o20 o20 o20 20 20 o20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 06 160 40 320 4640 160 320 160 320 o20 o20 o20 o20 o20 o20
JHU 07 80 80 160 4640 4640 80 40 320 o20 o20 o20 o20 o20 o20
JHU 08 20 o20 20 20 o20 o20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 09 320 40 80 4640 40 80 40 80 o20 o20 o20 o20 o20 o20
JHU 10 40 o20 o20 4640 40 o20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 11 o20 o20 o20 o20 o20 o20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 12 160 20 20 320 80 20 20 20 o20 20 o20 o20 o20 o20
JHU 13 320 o20 40 4640 80 o20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 14 80 20 20 160 40 o20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 15 4640 20 20 4640 40 80 40 160 o20 o20 o20 o20 o20 o20
JHU 16 320 o20 20 320 40 o20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 17 80 o20 o20 80 20 o20 o20 o20 NT NT o20 o20 o20 o20
JHU 18 40 o20 20 80 40 o20 o20 40 o20 o20 o20 o20 o20 o20
JHU 19 4640 o20 20 4640 20 20 o20 o20 NT oNT o20 o20 o20 o20
JHU 20 80 40 20 160 320 160 o20 o20 o20 o20 o20 o20 o20 o20
JHU 21 80 o20 80 320 80 o20 o20 o20 o20 o20 o20 o20 o20 o20
JHU 22 160 80 320 160 160 40 80 80 4640 4640 80 80 320 40
NT – not tested.
a 60% reduction measured by Plaque Reduction Neutralization Test (PRNT60).
b Sylvatic DENV-2 strains.
c Sylvatic DENV-1 strain.
A.P. Durbin et al. / Virology 439 (2013) 34–41 37strain and the endemic and sylvatic strains (Table 1), genetic P-
distances between the amino acid sequences of the structural
proteins were calculated. As expected, the structural proteins of
rDEN4D30 were much more similar to those of the endemic
DENV-4 strains than to that of the sylvatic E glycoprotein, with
nearly 100% amino acid sequence identity between the vaccine
strain and its parent 814669, followed by INH6412 (99.4%),
Haiti73 (99.3%), IndiaG11337 (97.3%) and H241 (97.0%). The
sylvatic strains’ structural proteins were all 95% identical to the
vaccine strain. These distances were plotted against the log
PRNT60 titers for each vaccine recipient and subjected to regres-
sion analysis. For the rDEN4D30 recipients, 18 of the 22 sera
demonstrated a positive relationship between the genetic relat-
edness of the neutralized virus to the vaccine strain and the
neutralization titer and, of these, 11 of the 18 were statistically
signiﬁcant (Po0.05). The only sera that failed to show a relation-
ship were JHU 5 and JHU 11 (non-neutralizing sera), the weakly
neutralizing sera JHU 2, and the potently neutralizing sera JHU 6.
Of note, the less potently neutralizing rDEN4D30-200, 201
vaccinee sera did not show a consistent relationship between
genetic distance and neutralization titer. Of the 19 sera tested,
only 11 showed a positive relationship between neutralization
titer and genetic distance, and of these 11, only 2 had a
statistically signiﬁcant correlation (214.01.01 and 214.01.13). This
likely is because of the overall lower antibody titers induced by
these more attenuated vaccines. This explanation is supported by
the observation that these vaccinees showed reduced homotypic
neutralization at 180 days post vaccination.
Neutralization studies of human primary convalescent sera
We also assessed the ability of convalescent sera collected
from primary DENV-4 pastients to neutralize sylvatic and ende-
mic DENV-4, (Table 4), including (i) sera obtained 9–21 days(Puerto Rico and Singapore) or up to a year (Mexico) after onset
(Table 4), as part of routine national surveillance programs, (ii)
very late convalescent sera (deﬁned as those collected 42 years
after documented DENV infection) obtained as part of an ongoing
dengue in traveler study (French West Indies and Honduras) and,
(iii) anonymous sera from a Sri Lankan blood bank (length of
convalescence unknown) and a reference serum collection (Thai-
land). Primary DENV infections were deﬁned by the capture
IgM:IgG ratio during the acute phase of disease (0–5 days after
onset of symptoms) (Falconar et al., 2006) or by a monotypic
neutralization proﬁle on late convalescent sera. Because a limited
volume of DENV-4 primary convalescent sera was available, we
were unable to evaluate their neutralization capacity with a large
collection of DENV-4 strains. Of the early convalescent Puerto
Rico sera, all but one (PR-A02 with India G11337 strain), robustly
neutralized of both endemic and sylvatic DENV-4 (PRNT60 40–
41280) (Table 5). Sera obtained from Puerto Rico and Singapore
exhibited weak to modest heterotypic neutralization of endemic
DENV-1-3 or sylvatic DENV-1 and -2 (PRNT60¼20–320), except
serum PR-A04, which strongly neutralized the sylvatic DENV-1
strain (PRNT6041280). Several sera exhibited no heterotypic
virus neutralization of endemic DENV-1-2 or sylvatic DENV-2
strains (PRNT60o20) (Table 5). Notably, both sera from Mexico
weakly neutralized both endemic and sylvatic DENV-4 (PRNT60 20–
40), but not endemic DENV-1-3 or sylvatic DENV-1 and -2
(PRNT60o20), whereas one serum exhibited a relatively strong virus
neutralizing activity against sylvatic DENV-1 (PRNT60¼160)(Table 5).
Because these sera were collected several months after infection
(Table 4), the lack of heterotypic neutralization is consistent with
transient heterotypic cross-protection after infection. The relatively
robust heterotypic responses observed in PR-A04 andMX-01 samples
suggest that the patients had a previously undiagnosed, heterologous
DENV infection. This concept was proposed by Halstead (Halstead
et al., 1983) as a mechanism of DENV immune response involved in
Table 4
Epidemiologic and demographic history of human primary convalescent DENV-4 used in this study.
Origin Ethnic background Age Sex Onseta,c Collectionb,c Diagnosis
Puerto Rico (PR-A01) Hispanic 39 M 12/07/1994 12/16/1994 DF
Puerto Rico (PR-A02) Hispanic 43 F 09/12/1995 09/19/1995 DHF
Puerto Rico (PR-A03) Hispanic 10 F 01/15/1997 01/21/1997 DF
Puerto Rico (PR-A04) Hispanic 48 M 09/09/1988 09/16/1988 DFd
Puerto Rico (PR-A05) Hispanic 29 M 06/11/1996 06/17/1996 DF
Puerto Rico (PR-A06) Hispanic 35 F 03/06/1996 03/12/1996 DHF
Puerto Rico (PR-A07) Hispanic 17 F 12/01/1991 12/18/1991 DFd
Puerto Rico (PR-A08) Hispanic 15 M 09/01/1993 09/09/1993 DF
Puerto Rico (PR-A09) Hispanic 75 M 10/10/1993 10/22/1993 DF
Puerto Rico (PR-A10) Hispanic 29 M 10/13/1993 10/20/1993 DHF
Puerto Rico (PR-A11) Hispanic 21 M 11/10/1993 11/27/1993 DFd
Puerto Rico (PR-A12) Hispanic 10 M 12/01/1991 12/13/1991 DFd
Mexico Hispanic 40 M 08/30/2008 02/04/2009 DF
Mexico Hispanic 20 F 06/25/2008 08/04/2009 DF
Singapore Chinese 25 M 07/17/2006 08/10/2006 DF
United States Caucasian 26 F 2005e 05/01/2009 DF
United States Caucasian 52 M 2007f 05/08/2009 DF
Thailandg Unknown Unknown Unknown Unknown Late convi Unknown
Sri Lankah Unknown Unknown Unknown Unknown Late convk Unknown
Abbreviations: M—male; F—female.
a Indicates date when onset of symptoms occurred.
b Indicates date when collection of serum occurred.
c Date is represented as: month/day/year.
d Cases of presumptive DF based on the case investigation form only. No additional information was received after the sample was obtained and consequently we do
not know how the clinical presentation progressed.
e Infection acquired in the French West Indies.
f Infection acquired in Honduras.
g WHO primary Thai DENV-4 reference sera (3 samples).
h Sera screened from Colombo, Sri Lanka, blood donors.
i Sera were collected greater than 2 years after documented DENV infection.
k Length of convalescence for the Sri Lankan blood bank donor is unknown.
Table 5
Homotypic and Heterotypic DENV-4 Neutralizationa by Convalescent Patient Serab.
DENV-4
Immune Serab
Virus
Endemic DENV-4 Sylvatic DENV-4 DENV-2 DENV-3 DENV-1
814669 H241 India G11337 INH6412 Haiti73 P75-215 P75-514 P73-1120 16681 DKD811c P8-1407c JKT85-934 OBS7690 P72-1244d
PR-A01 NT 41280 640 41280 41280 41280 41280 41280 o20 NT 80 41280 160 160
PR-A02 NT 160 o20 320 160 160 80 40 20 NT o20 80 o20 o20
PR-A03 NT 640 80 640 320 640 320 80 20 NT 80 320 160 80
PR-A04 NT 320 80 320 160 160 320 160 NT NT 160 640 NT 41280
PR-A05 NT 40 80 160 320 80 160 80 o20 40 40 160 o20 40
PR-A06 NT 640 160 320 320 80 320 160 o20 o20 o20 40 o20 40
PR-A07 NT 1280 320 640 320 320 640 320 o20 NT 80 320 160 320
PR-A08 NT 320 80 320 320 160 320 160 o20 o20 80 320 o20 80
PR-A09 NT 320 320 160 320 320 320 1280 o20 80 80 40 160 80
PR-A10 NT 160 160 160 320 320 80 80 o20 o20 80 40 160 40
PR-A11 NT 160 160 160 160 160 160 160 o20 40 80 40 80 40
PR-A12 NT 320 160 320 320 160 160 40 o20 NT 40 40 40 40
MX-01 NT 20 40 20 20 40 20 40 NT NT o20 o20 NT 160
MX-02 NT 40 20 40 40 20 40 20 o20 o20 o20 o20 o20 o20
SG-01 NT 640 640 41280 160 320 160 160 NT NT 80 40 160 160
DT100e 160 NT NT 160 320 160 NT 80 NT NT NT NT NT NT
DT102e 160 NT NT 320 160 40 NT 640 NT NT NT NT NT NT
DV002e 40 NT NT 80 80 40 NT 80 NT NT NT NT NT NT
GS58e 20 NT NT 40 40 20 NT 20 NT NT NT NT NT NT
SS06/105e 320 NT NT 640 320 80 NT 40 NT NT NT NT NT NT
SS06/302e 41280 NT NT 41280 320 80 NT 40 NT NT NT NT NT NT
SS07/333e 41280 NT NT 41280 41280 160 NT 80 NT NT NT NT NT NT
a 60% reduction measured by plaque reduction neutralization test (PRNT60).
b Sera were obtained from conﬁrmed primary DENV-4 infections from patients in Puerto Rico (PR), Mexico (MX) and Singapore (SG).
c Sylvatic DENV-2 strains.
d Sylvatic DENV-1 strain.
e Monotypic proﬁle conﬁrmed against WHO reference strains (DENV-1 West Pac 74, DENV-2 S16803, DENV-3 CH53498).
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A.P. Durbin et al. / Virology 439 (2013) 34–41 39sequential infections. In such instances, the immune response to a
secondary infection is dominated by the proliferation of cross-
reacting memory cells induced by the primary infection, which may
be of lower afﬁnity for the secondary challenging antigen.
The late convalescent sera DT100 (West Indies, 4 years post
acute infection) and DT102 (Honduras, 2 years post acute infec-
tion) showed that durable and broad homotypic neutralization
can persist several years after infection. The blood donor sera
DV002 and GS58, both from Sri Lanka, showed a less robust but
equally broad neutralization against both endemic and sylvatic
viruses. The DENV-4 reference sera, SS06/105, 302 and SS07/333
were interesting in that they were broadly neutralizing but had as
much as a 16-fold difference in neutralization titers between
endemic and sylvatic DENV-4. This suggests that, while natural
infection induces broad intraserotypic neutralization, there can be
signiﬁcant variation within that serotype, underscoring the role of
genotype-speciﬁc epitopes in antibody mediated protection.
Our results demonstrate the ability of convalescent sera collected
after primary DENV-4 infection as well as from DENV-4-vaccinees to
neutralize genetically diverse DENV-4. The observed protection is
mainly due to homotypic immunity, and consistent with Sabin’s
observations, we observed only a transient heterotypic immunity.
Sera from human vaccinees collected at 42 and 180 days following
vaccination with rDEN4D30-200,201 or at day 42 after rDEN4D30
vaccination exhibited limited to no heterotypic immunity. Further-
more, our rDEN4D30-200,201 data corroborate the reduced levels of
neutralization titers observed previously, attributed to the greater
attenuation of this candidate (McArthur et al., 2008).
Several investigators have suggested that amino acid differ-
ences in the lateral ridge of domain III of the E glycoprotein
(Cockburn et al., 2012; Endy et al., 2004; Wahala et al., 2010;
Zulueta et al., 2006) are responsible for variable intra-serotypic
neutralization. For the viruses in this study, there are thirteen
variable amino acid positions on the E glycoprotein that are
conserved between the endemic and sylvatic strains. Five are in
domain I, only one occurs in domain II, and the remaining eight
residue differences are in domain III, of which only two occur
along the lateral ridge (A329T and V382A). It is unlikely that these
two polymorphisms alone would account for differences in
neutralization. Moreover, recently published research suggests
the ﬂavivirus targets of human antibodies are likely to be non-
EDIII or quaternary epitopes that potentially involve residues in
multiple domains in variable neutralization (de Alwis et al., 2012).
As noted above, within-serotype neutralization varied broadly.
For the rDEN4D30 vaccinee sera, neutralization titer was signiﬁ-
cantly correlated with genetic distances between the vaccine
strain and the tested strains in half the sera tested. Additionally,
the PRNT60 titers of recent convalescent sera against endemic and
sylvatic strains did not vary signiﬁcantly for most samples.
Collectively, our data suggest that re-emergence of sylvatic
DENV-4 into the human transmission cycle may be limited by
homotypic humoral immunity, induced either by vaccination or
prior natural DENV-4 infection. The potential licensing of effective
DENV vaccines raises the prospect of control or even eradication
of the human transmission cycle, which relies solely on human-
mosquito-human transmission. However, sylvatic transmission
cycles are not amenable to control by human vaccination and
epidemiological evidence suggests that sylvatic DENV come into
regular contact with humans and can cause severe disease
(Cardosa et al., 2009; Franco et al., 2011) or transient spill-over
to urban settings (Carey et al., 1971; Vasilakis et al., 2008c).
Furthermore, recent experimental evidence indicates a low to
non-existent adaptive barrier for the emergence of sylvatic DENV
into the human population (Vasilakis et al., 2007), implying that
re-emergence is a clear and present danger. Therefore, even as
efforts to control circulation of human dengue intensify in amanner analogous to historic efforts to control urban yellow
fever, reduction and ultimate eradication of dengue from human
populations solely due to vaccination campaigns could be, at best,
short-lived. The urban yellow fever experience suggests that
successful eradication of dengue will hinge on sustained vaccina-
tion of susceptible populations, including those who are at risk
from the introduction of sylvatic DENV, with potently immuno-
genic and long-lasting vaccines, as well as control of the urban
mosquito vectors.Material and methods
Ethical considerations
Written consent to participate in the study was obtained from
each subject enrolled in the dengue vaccine studies. All data were
handled anonymously and conﬁdentially. The studies were con-
ducted at the Center for Immunization Research (CIR) at the John
Hopkins Bloomberg School of Public Health under an investiga-
tional new drug application for both rDEN4D30-200,201 (BB-IND
12670) and rDEN4D30 (BB-IND 12977). The University of Texas
Medical Branch Institutional Review Board reviewed the study as
protocol UTMB-IRB#10-047. Human sera from Singapore were
from the early dengue infection and outcome study (Low et al.,
2006), and were collected following written informed consent
and approved by the National Healthcare Group Domain Speciﬁc
Review Board (DSRB 5B/05/013). Human sera from Puerto Rico,
and Mexico, obtained from routine surveillance, and sera from US
travelers were de-identiﬁed and approved for this research study
under IRB exemption 4797 at the CDC, CI986-L62 Mexico and 08-
0895 UNC, respectively.
Cell cultures
Monolayer cultures Vero cells (obtained from American
Type Culture Collection, Bethesda, MD) were grown at 37 1C in
Dulbecco’s minimal essential medium (DMEM) (4.5 g/L D-Glu-
cose) with 10% heat-inactivated fetal bovine serum (FBS) and 1%
penicillin/streptomycin (P/S). C6/36 mosquito cells (a generous
gift from Ilya Frolov) were grown at 28 1C in Dulbecco’s minimal
essential medium (DMEM) (4.5 g/L D-Glucose) with 10% heat-
inactivated FBS, 1% P/S and 1% tryptose phosphate broth (TPB).
Viruses
DENV-1,-2, -3 and -4 isolates of low passage history (Table 1),
were obtained from the World Reference Center for Emerging
Viruses and Arboviruses, University of Texas Medical Branch. The
Dominica strain, 814669, from which both tested DENV-4 vaccine
candidates were derived, was provided by Dr. Anna Durbin. Viral
isolates were passaged once in C6/36 cultures to obtain high titer
stocks. Supernatants were clariﬁed from cellular debris by low-
spin centrifugation (630 g, 20 min, 4 1C) stabilized with the
addition of 10 SPG (2.18 M Sucrose, 0.038 M KH2PO4, 0.072 M
K2HPO4 and 0.054 M L-glutamate), and stored at 80 1C.
Vaccine viruses
The rDEN4D30 vaccine candidate was derived from the DENV-4
strain 814669 (Dominica 1981) by the removal of 30-nucleotides (nt)
from the 30 UTR of the genome (Durbin et al., 2001). The rDEN4D30-
200,201 vaccine virus was derived from the rDEN4D30 vaccine virus
by paired charge-to-alanine mutagenesis. (Hanley et al., 2004;
McArthur et al., 2008). The rDEN4D30-200,201 virus was generated
as described previously in Hanley et al. (2004).
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Serum samples were collected as part of previously described
DENV vaccine trials (Durbin et al., 2011; McArthur et al., 2008).
Healthy adult male and non-pregnant female volunteers were
recruited from metropolitan Baltimore, Maryland. Informed con-
sent was obtained from each enrolled healthy volunteer, between
18 and 50 years of age, in accordance with the Code of Federal
Regulations (CFR21, Part 50). Each enrolled volunteer met the
following eligibility criteria: normal ﬁndings during physical
examination; negative for antibodies to all DENV, yellow fever
virus, West Nile virus, St. Louis encephalitis virus, Japanese
encephalitis virus, human immunodeﬁciency virus, and hepatitis
C virus; negative for hepatitis B surface antigen; normal values for
complete blood count (CBC), and urinalysis. Additional safety-
related exclusion criteria were also applied. Female volunteers
were required to have a negative urine pregnancy test at least
three days prior to vaccination and on the day of vaccination and
to agree to use contraception or abstain from sexual intercourse
for the duration of the study. Sera provided for this study
represent collections at day 42 post vaccination as described in
McArthur et al. (2008).Human primary convalescent sera
Sera from convalescent patients after primary infection
with DENV-4 obtained 9–21 days (Puerto Rico and Singapore)
or up to a year (Mexico) after the onset of symptoms (Table 4),
were obtained from routine surveillance, and were de-
identiﬁed and approved for this research study under IRB
exemption 4797 at the CDC. Late convalescent sera were
collected as part of an ongoing dengue in traveler study under
University of North Carolina (UNC) IRB approval 08-0895.
Anonymous blood bank and reference sera were kindly pro-
vided by the lab of Aravinda de Silva, UNC School of Medicine,
Department of Microbiology.PRNT and immunostaining
PRNTs were performed in 12-well, Vero-microplate-cell cultures,
using a ﬁxed virus inoculum [800 focus forming units (FFU)]
against varying serum dilutions (1:10–1:640). Serum samples were
diluted in minimal essential medium (MEM), containing 2% fetal
bovine serum. Virus was mixed with an equal volume of each serum
dilution and the mixture was incubated 1hr at 37 1C. Then, 250 mL of
the serum-virus mixture was placed into Vero cultures and incu-
bated 1hr at 37 1C. A 1.5 mL volume of 4% methycellulose in
OPTIMEM-I overlay was placed in each well and the plates were
incubated at 37 1C for 4–5 days. The plates were then ﬁxed with 1:1
methanol:acetone and foci were stained immunologically and
counted to determine the level of virus neutralization, as described
previously (Vasilakis et al., 2007, 2008a). The PRNT titers were
scored as reciprocal of the highest dilution of serum that inhibited
60% of foci.Statistical analyses
All statistical comparisons and regression analyses were calculated
in JMP v7.0 (Cary, NC). Mean log titers were compared by one-way
ANOVA. Po0.05 was considered signiﬁcant in all comparisons.
Correlations between PRNT60 titers and genetic P-distances were
tested using a standard least squares model. P-distances between
DENV-4 structural protein amino acid sequences were calculated
with MEGA V5.0 (Tamura et al., 2011) default settings.Acknowledgments
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